Picozzi, V. J., Varghese, A. M., Oberstein, P. E., Hidalgo, M., Wolpin, B. M., Lim, K., McGlothlin, A., Graves, T., Detry, M. A., Fitzgerald, M., Bosse, A., Moravek, C., Pedersen, S., Berkenblit, A., Chen, J., Carrier, E., Adib, D. R., Berry, D. A., Simeone, D. M., Ko, A. H. (2025). Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.673